Fulcrum Therapeutics (FULC) Projected to Post Quarterly Earnings on Wednesday

Fulcrum Therapeutics (NASDAQ:FULC) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.01. On average, analysts expect Fulcrum Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $7.81 on Monday. The business’s 50 day moving average price is $7.10 and its 200-day moving average price is $4.90. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $10.13. The company has a market cap of $421.58 million, a price-to-earnings ratio of -111.56 and a beta of 2.37.

Analysts Set New Price Targets

Several research analysts have commented on the company. Leerink Partners upgraded Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $4.00 to $12.00 in a report on Friday, May 23rd. Cantor Fitzgerald upgraded Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 price target on the stock in a report on Thursday, May 15th. Piper Sandler reiterated an “overweight” rating and issued a $9.00 price target (up from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. Finally, Leerink Partnrs upgraded Fulcrum Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.29.

Institutional Trading of Fulcrum Therapeutics

An institutional investor recently raised its position in Fulcrum Therapeutics stock. Jane Street Group LLC lifted its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 62.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 117,816 shares of the company’s stock after purchasing an additional 45,157 shares during the quarter. Jane Street Group LLC owned about 0.22% of Fulcrum Therapeutics worth $339,000 as of its most recent SEC filing. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.